Inhibikase Therapeutics, Inc.
Inhibikase Therapeutics, Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Biological Products, (No Diagnostic Substances).
The next scheduled catalyst is Next quarterly earnings (projected) on November 11, 2026, a projected date rather than a confirmed one. There are 3 upcoming events on record.
Cash runway is approximately 76.3 months based on the most recent reported cash position and quarterly operating burn as of 2025-12-31.
| Date | Event | Type | Phase |
|---|---|---|---|
| November 11, 2026 est. | Next quarterly earnings (projected) | Earnings | — |
| June 15, 2029 | An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH) | Trial Milestone | Phase 3 |
| June 30, 2030 | Open-Label Study of IKT-001 in Pulmonary Arterial Hypertension (PAH) | Trial Milestone | Phase 3 |
Track IKT alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open IKT in the tracker| Date | Event | Type | Phase |
|---|---|---|---|
| September 8, 2026 | 8-K filed: Reg FD disclosure | Filing | — |
| August 11, 2026 | Quarterly results filed (8-K) | Earnings | — |
| July 23, 2026 | 8-K filed: Reg FD disclosure | Filing | — |
| July 14, 2026 | 8-K filed: Other event | Filing | — |
| June 29, 2026 | 8-K filed: Leadership change | Corporate | — |
| May 12, 2026 | Quarterly results filed (8-K) | Earnings | — |
| April 7, 2026 | 8-K filed: Reg FD disclosure | Filing | — |
| March 26, 2026 | Quarterly results filed (8-K) | Earnings | — |
| December 19, 2025 | 8-K filed: Other event | Filing | — |
| November 21, 2025 | 8-K filed: Material agreement, Other event | Corporate | — |
| November 20, 2025 | 8-K filed: Other event | Filing | — |
| November 14, 2025 | Quarterly results filed (8-K) | Earnings | — |
| August 14, 2025 | Quarterly results filed (8-K) | Earnings | — |
| May 14, 2025 | Quarterly results filed (8-K) | Earnings | — |
| April 14, 2025 | 8-K filed: Leadership change, Reg FD disclosure | Corporate | — |
| June 30, 2024 | A Dose Calibration Study Comparing IkT-001Pro to Imatinib Mesylate 400mg | Trial Milestone | Phase 1 |
Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.